Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers). Board expanded from 7 to 8 members with Nerissa Kreher, M.D. joining effective July 1, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 7 to 8 members with Nerissa Kreher, M.D. joining effective July 1, 2026
- Kreher brings clinical development and rare-disease biotechnology experience, potentially strengthening pipeline and regulatory oversight
- Independent Nasdaq director received approximately $450,000 initial equity award
- Future annual director equity grants carry approximately $300,000 grant-date value
- CEO John Shannon became Board Chair, with Marla S. Persky appointed Lead Independent Director
Item 7.01 · Regulation FD Disclosure
- Dr. Kreher appointed to Xeris Biopharma’s Board of Directors
- Related Board leadership changes announced
- Exhibit 99.1 contains the press release and detailed governance changes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.